Daxas for COPD Therapy (DACOTA).

Trial Profile

Daxas for COPD Therapy (DACOTA).

Completed
Phase of Trial: Phase IV

Latest Information Update: 10 Nov 2016

At a glance

  • Drugs Roflumilast (Primary)
  • Indications Chronic obstructive pulmonary disease
  • Focus Therapeutic Use
  • Acronyms DACOTA
  • Sponsors Takeda; Takeda Pharmaceuticals International GmbH
  • Most Recent Events

    • 04 May 2012 Takeda Global Research and Development Center added as company and lead trial centre as reported by ClinicalTrials.gov.
    • 04 May 2012 Planned end date changed from 1 Mar 2012 to 1 Jun 2012 as reported by ClinicalTrials.gov.
    • 04 Jan 2012 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top